Overview
Marc Dechamps is chief executive officer of Bioxodes, a role he took up in October 2022, and is based in Waterloo. Since March 2022 he has been academic director and founder of the Advanced Master in Biotech & MedTech Ventures at the Solvay Brussels School of Economics and Management (SBS-EM) - ULB, and he chairs the boards of Investsud Tech and Investsud Innovation at INVESTSUD. He also sits on an advisory board at eu, serves as an administrator of BioGenCell Europe, and founded XMF Consulting, which he has led as managing director since July 2016.
He was an independent board member of OSE Immunotherapeutics from 2024 to 2025 and a board member of HealthTech For Care from 2022 to 2026. At the Council of European BioRegions - CEBR he was a board member from 2019 and president of the board from 2020 until 2023. He was director of international affairs at BioWin - The Health Cluster of Wallonia and later handled its international representation.
Earlier he was interim CEO of etherna, and chief operating officer then managing director of Delphi Genetics. At ViiV Healthcare he held European strategy and operations roles between 2009 and 2015, following posts at GSK as business unit director CNS and executive director, commercial specialty care and vaccines.
He holds a master's degree in biology from the Université de Namur.
Career history
In the news
- 𝐁𝐈𝐎𝐗-101 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 𝐫𝐞𝐜𝐨𝐯𝐞𝐫𝐲 𝐚𝐧𝐝 𝐫𝐞𝐝𝐮𝐜𝐞𝐝 𝐬𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲 𝐛𝐫𝐚𝐢𝐧 𝐢𝐧𝐣𝐮𝐫𝐲 𝐚𝐟𝐭𝐞𝐫 𝐢𝐧𝐭𝐫𝐚𝐜𝐞𝐫𝐞𝐛𝐫𝐚𝐥 𝐡𝐞𝐦𝐨𝐫𝐫𝐡𝐚𝐠𝐞 𝐢𝐧 𝐧𝐞𝐰𝐥𝐲 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐚𝐭𝐚 Our preclinical data on BIOX-101 in intracerebral hemorrhage (ICH) are published in the peer-reviewed journal 𝐂𝐍𝐒 𝐍𝐞𝐮𝐫𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞 & 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, with Stéphanie Demoulin, PhD, as corresponding author, together with ETAP-Lab and Prof. Denis Vivien at CHU Caen
- Chief Executive Officer Marc Dechamps will be speaking at the 4𝐭𝐡 𝐁𝐞𝐧𝐞𝐥𝐮𝐱 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦, bringing together leaders from biotech, pharma, investment and innovation to discuss the future of drug development. This year's theme,"𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐭𝐡𝐞 𝐖𝐚𝐲 𝐖𝐞 𝐓𝐡𝐢𝐧𝐤", will explore new perspectives on advancing drug development and translating scientific innovation into therapies that can benefit patients. At Bioxodes, we are applying that mindset to intracerebral
- 𝐁𝐈𝐑𝐂𝐇 𝐏𝐡𝐚𝐬𝐞 2𝐚 𝐝𝐚𝐭𝐚 𝐬𝐡𝐨𝐰 𝐬𝐭𝐚𝐭𝐢𝐬𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐫𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐩𝐞𝐫𝐢𝐡𝐞𝐦𝐚𝐭𝐨𝐦𝐚𝐥 𝐞𝐝𝐞𝐦𝐚 𝐠𝐫𝐨𝐰𝐭𝐡 𝐰𝐢𝐭𝐡 𝐁𝐈𝐎𝐗-101 𝐢𝐧 𝐢𝐧𝐭𝐫𝐚𝐜𝐞𝐫𝐞𝐛𝐫𝐚𝐥 𝐡𝐞𝐦𝐨𝐫𝐫𝐡𝐚𝐠𝐞 Bioxodes today presented new imaging analyses and one-year functional outcomes from the BIRCH Phase 2a trial of BIOX-101 in a Late-Breaking Science oral presentation at the 18𝐭𝐡 𝐖𝐨𝐫𝐥𝐝 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 (#WSC2026) in Seoul, given by Dr. Dimitri Hemelsoet,
- 𝐓𝐢𝐦𝐞 𝐢𝐬 𝐛𝐫𝐚𝐢𝐧." As Bioxodes CEO Marc Dechamps emphasized last week at the 1𝐬𝐭 𝐀𝐧𝐧𝐮𝐚𝐥 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐦𝐩𝐚𝐜𝐭 𝐒𝐮𝐦𝐦𝐢𝐭 in Basel, every minute matters in stroke, but so does what happens after the initial event. Marc joined 𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐢𝐧 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐚𝐫𝐞: 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 & 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 panel for a wide-ranging discussion on where stroke care is heading. 𝐓𝐡𝐫𝐞𝐞 𝐤𝐞𝐲 𝐭𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬:
- 𝐏𝐑𝐄𝐒𝐒 𝐑𝐄𝐋𝐄𝐀𝐒𝐄: 𝐓𝐡𝐞 𝐟𝐢𝐧𝐚𝐥 𝐁𝐈𝐑𝐂𝐇 𝐝𝐚𝐭𝐚 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐬𝐞𝐥𝐞𝐜𝐭𝐞𝐝 𝐟𝐨𝐫 𝐚 𝐋𝐚𝐭𝐞-𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐨𝐫𝐚𝐥 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐭 𝐭𝐡𝐞 18𝐭𝐡 𝐖𝐨𝐫𝐥𝐝 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝐢𝐧 𝐒𝐞𝐨𝐮𝐥, 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚. The final Phase 2a data show statistically significant improvements with BIOX-101 across multiple secondary endpoints in acute intracerebral hemorrhage (ICH). They build on the positive results reported earlier this year and cover safety, imaging and
- Chief Executive Officer Marc Dechamps will join a panel discussion at COG Europe 2026 in Amsterdam to discuss one of the key challenges facing biotech companies today: securing funding to advance clinical development. The session,"𝐒𝐡𝐨𝐰 𝐌𝐞 𝐓𝐡𝐞 𝐌𝐨𝐧𝐞𝐲: 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐚𝐧𝐝 𝐏𝐨𝐬𝐢𝐭𝐢𝐨𝐧𝐢𝐧𝐠 𝐘𝐨𝐮𝐫 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬", will explore how biotech companies can successfully navigate the transition from discovery to clinical development, attract investment, and build compelling value propositions for
- Our Chief Executive Officer Marc Dechamps will join a panel discussion at the 1st European Healthcare Impact Summit, organized by Sachs Associates in Basel. Stroke remains one of the leading causes of death and disability worldwide, yet treatment options remain limited for patients suffering from intracerebral hemorrhage (ICH), the deadliest form of stroke and a condition for which no approved therapy exists. Marc will participate in the panel “𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐢𝐧 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐚𝐫𝐞: 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬,
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.